Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients

Annals of Surgical Oncology

Volumn 20, Issue 12, 2013, Pages 4008-4015

  Smit, Justin K ^a   Güler, Sahin ^a   Beukema, Jannet C ^a   Mul, Véronique E ^a   Burgerhof, Johannes G M ^a   Hospers, Geke A P ^a   Plukker, John Th M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGUS CANCER; FEMALE; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; RECURRENCE FREE SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SURVIVAL RATE;

EID: 84886085427     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3102-7     Document Type: Article

References (32)

1. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100:1184-7.
2. Crane LM, Schaapveld M, Visser O, Louwman MW, Plukker JT, van Dam GM. Oesophageal cancer in the Netherlands: increasing incidence and mortality but improving survival. Eur J Cancer. 2007;43:1445-51.
3. Netherlands cancer registry, 2013. http://www.cijfersoverkanker.nl/? language=en. Accessed 31 Jan 2013.
4. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681-92.
5. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-34.
6. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol. 2003;10:754-61.
7. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074-84.
8. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-7.
9. Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2011;80:996-1001.
10. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol. 2011;29:626-31.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.
12. Weitzen S, Lapane KL, Toledano AY, Hume AL, Mor V. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf. 2004;13:841-53.
13. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-81.
14. Rice TW, Blackstone EH, Rusch VW. 7th Edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17:1721-4.
15. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol. 2003;21:19-22.
16. van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006;94:1389-94.
17. Smit JK, Pultrum BB, van Dullemen HM, Van Dam GM, Groen H, Plukker JT. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. Am J Surg. 2010;200:446-53.
18. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680-6.
19. Bull AA, Meyerowitz BE, Hart S, Mosconi P, Apolone G, Liberati A. Quality of life in women with recurrent breast cancer. Breast Cancer Res Treat. 1999;54:47-57.
20. Camilleri-Brennan J, Steele RJ. The impact of recurrent rectal cancer on quality of life. Eur J Surg Oncol. 2001;27:349-53.
21. Northouse LL, Mood D, Kershaw T, Schafenacker A, Mellon S, Walker J, et al. Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol. 2002;20:4050-64.
22. Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA. Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat. 2004;87:45-57.
23. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med. 1993;329:1302-7.
24. Cwikiel W, Tranberg KG, Cwikiel M, Lillo-Gil R. Malignant dysphagia: palliation with esophageal stents - long-term results in 100 patients. Radiology. 1998;207:513-8.
25. Fan Y, Song HY, Kim JH, Park JH, Kim J, Jung HY, et al. Evaluation of the incidence of esophageal complications associated with balloon dilation and their management in patients with malignant esophageal strictures. AJR Am J Roentgenol. 2012;198:213-8.
26. Caspers RJ, Welvaart K, Verkes RJ, Hermans J, Leer JW. The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer. Radiother Oncol. 1988;12:15-23.
27. Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology - multifactorial decision support systems. Nat Rev Clin Oncol. 2012;10:27-40.
28. Trial register NCT01107639. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01107639?term=ruhstaller&rank=1. Accessed 31 Jan 2013.
29. Waddell T, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol. 2012;30(Suppl):LBA4000.
30. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J Clin Oncol. 2012;30:3932-8.
31. NCI RTOG 1010 trial register: NCT01196390. http://clinicaltrials.gov/ show/NCT01196390 (2012). Accessed 31 Jan 2013.
32. Wolthuis AM, Penninckx F, Haustermans K, De Hertogh G, Fieuws S, Van Cutsem E, et al. Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol. 2012;19:2833-41.